Dimethyl sulfoxide (DMSO) was from Fisher Scientific. AMPA was from Cayman Chemical and NBQX was from Alomone Labs.
Recombinant GluA1 and 14-3-3ε were from Origene. Recombinant Nedd4-2 was from Abnova. R18 was from Sigma-Aldrich.
Cycloheximide,
poly-D-lysine and
Protein A/G beads were from Santa Cruz Biotechnology. The antibodies used in this study were purchased from Santa Cruz Biotechnology (
anti-α-Tubulin), Cell Signaling (anti-Nedd4-2,
anti-pan-14-3-3, anti-N-cadherin and anti-Ubiquitin), Millipore (
anti-GluA1), Abcam (
anti-MAP2), Thermo Scientific (
anti-HA) and GenScript Corporation (
anti-Gapdh). The epilepsy-associated mutations were generated using
site-directed mutagenesis reagent (Agilent) to introduce mutations into pCI-HA-Nedd4-2 [15 (
link)]. The primers used are as below.
S233L: 5’-GGACGTGTCCTCGGAGTTGGACAATAACATCAGAC-3’,
5’-GTCTGATGTTATTGTCCAACTCCGAGGACACGTCC-3’;
E271A: 5’- GGGCGGGGATGTCCCCGCGCCTTGGGAGACCATTTC-3’,
5’- GAAATGGTCTCCCAAGGCGCGGGGACATCCCCGCCC-3’;
H515P: 5’- CGTTTGAAATTTCCAGTACCTATGCGGTCAAAGACATC-3’,
5’- GATGTCTTTGACCGCATAGGTACTGGAAATTTCAAACG-3’.
Zhu J., Lee K.Y., Jewett K.A., Man H.Y., Chung H.J, & Tsai N.P. (2017). Epilepsy-associated gene Nedd4-2 mediates neuronal activity and seizure susceptibility through AMPA receptors. PLoS Genetics, 13(2), e1006634.